At the news
? BULLISHIMPACT 8/10 8-K filed Apr 13, 2026 at 06:05 ET
IDEAYA Biosciences announced positive Phase 2/3 clinical trial results for darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma, showing a 58% reduction in risk of progression and significantly improved median progression-free survival (6.9 vs 3.1 months). The company plans to submit a New Drug Application (NDA) in the second half of 2026.
- Darovasertib combination met primary endpoint of statistically significant improvement in median PFS (6.9 months vs 3.1 months) with hazard ratio of 0.42 (p < 0.0001)
- ORR was 37.1% in the darovasertib arm vs 5.8% in the investigator choice therapy arm (p < 0.0001)
- 5 complete responses observed in darovasertib arm, none in control arm
- Median DOR was 6.8 months in the darovasertib arm
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access